These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24879978)

  • 21. Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury.
    Ulzurrun E; Stephens C; Crespo E; Ruiz-Cabello F; Ruiz-Nuñez J; Saenz-López P; Moreno-Herrera I; Robles-Díaz M; Hallal H; Moreno-Planas JM; Cabello MR; Lucena MI; Andrade RJ
    Liver Int; 2013 Oct; 33(9):1378-85. PubMed ID: 23701583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
    Nicoletti P; Aithal GP; Bjornsson ES; Andrade RJ; Sawle A; Arrese M; Barnhart HX; Bondon-Guitton E; Hayashi PH; Bessone F; Carvajal A; Cascorbi I; Cirulli ET; Chalasani N; Conforti A; Coulthard SA; Daly MJ; Day CP; Dillon JF; Fontana RJ; Grove JI; Hallberg P; Hernández N; Ibáñez L; Kullak-Ublick GA; Laitinen T; Larrey D; Lucena MI; Maitland-van der Zee AH; Martin JH; Molokhia M; Pirmohamed M; Powell EE; Qin S; Serrano J; Stephens C; Stolz A; Wadelius M; Watkins PB; Floratos A; Shen Y; Nelson MR; Urban TJ; Daly AK;
    Gastroenterology; 2017 Apr; 152(5):1078-1089. PubMed ID: 28043905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.
    Amacher DE
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):335-47. PubMed ID: 22288564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA associations with infliximab-induced liver injury.
    Bruno CD; Fremd B; Church RJ; Daly AK; Aithal GP; Björnsson ES; Larrey D; Watkins PB; Chow CR
    Pharmacogenomics J; 2020 Oct; 20(5):681-686. PubMed ID: 32024945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.
    Nicoletti P; Dellinger A; Li YJ; Barnhart HX; Chalasani N; Fontana RJ; Odin JA; Serrano J; Stolz A; Etheridge AS; Innocenti F; Govaere O; Grove JI; Stephens C; Aithal GP; Andrade RJ; Bjornsson ES; Daly AK; Lucena MI; Watkins PB; ; ;
    Gastroenterology; 2023 Mar; 164(3):454-466. PubMed ID: 36496055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced liver injury.
    Leise MD; Poterucha JJ; Talwalkar JA
    Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver injury caused by drugs: an update.
    Stirnimann G; Kessebohm K; Lauterburg B
    Swiss Med Wkly; 2010; 140():w13080. PubMed ID: 20927685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles.
    Nicoletti P; Aithal GP; Chamberlain TC; Coulthard S; Alshabeeb M; Grove JI; Andrade RJ; Bjornsson E; Dillon JF; Hallberg P; Lucena MI; Maitland-van der Zee AH; Martin JH; Molokhia M; Pirmohamed M; Wadelius M; Shen Y; Nelson MR; Daly AK;
    Clin Pharmacol Ther; 2019 Jul; 106(1):245-253. PubMed ID: 30661239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury.
    Donaldson PT; Daly AK; Henderson J; Graham J; Pirmohamed M; Bernal W; Day CP; Aithal GP
    J Hepatol; 2010 Dec; 53(6):1049-53. PubMed ID: 20800921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using genome-wide association studies to identify genes important in serious adverse drug reactions.
    Daly AK
    Annu Rev Pharmacol Toxicol; 2012; 52():21-35. PubMed ID: 21819236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury.
    Jin S; Li X; Fan Y; Fan X; Dai Y; Lin H; Cai W; Yang J; Xiang X
    Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):508-517. PubMed ID: 31240859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.
    Urban TJ; Shen Y; Stolz A; Chalasani N; Fontana RJ; Rochon J; Ge D; Shianna KV; Daly AK; Lucena MI; Nelson MR; Molokhia M; Aithal GP; Floratos A; Pe'er I; Serrano J; Bonkovsky H; Davern TJ; Lee WM; Navarro VJ; Talwalkar JA; Goldstein DB; Watkins PB; ; ; ; ;
    Pharmacogenet Genomics; 2012 Nov; 22(11):784-95. PubMed ID: 22968431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).
    Pachkoria K; Lucena MI; Ruiz-Cabello F; Crespo E; Cabello MR; Andrade RJ;
    Br J Pharmacol; 2007 Mar; 150(6):808-15. PubMed ID: 17279092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
    Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
    J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.
    Urban TJ; Nicoletti P; Chalasani N; Serrano J; Stolz A; Daly AK; Aithal GP; Dillon J; Navarro V; Odin J; Barnhart H; Ostrov D; Long N; Cirulli ET; Watkins PB; Fontana RJ; ; ;
    J Hepatol; 2017 Jul; 67(1):137-144. PubMed ID: 28323125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.
    Lucena MI; Andrade RJ; Martínez C; Ulzurrun E; García-Martín E; Borraz Y; Fernández MC; Romero-Gomez M; Castiella A; Planas R; Costa J; Anzola S; Agúndez JA;
    Hepatology; 2008 Aug; 48(2):588-96. PubMed ID: 18666253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.
    Chen R; Zhang Y; Tang S; Lv X; Wu S; Sun F; Xia Y; Zhan SY
    J Clin Pharm Ther; 2015 Feb; 40(1):110-5. PubMed ID: 25250564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility.
    Alfirevic A; Pirmohamed M
    Clin Pharmacol Ther; 2012 Sep; 92(3):376-80. PubMed ID: 22850601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients.
    Li X; Jin S; Fan Y; Fan X; Tang Z; Cai W; Yang J; Xiang X
    Biomed Pharmacother; 2019 Sep; 117():109095. PubMed ID: 31202168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.
    Fontana RJ
    Gastroenterology; 2014 Apr; 146(4):914-28. PubMed ID: 24389305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.